To investigate the protective effect of deferoxamine (DFO) administration in comparison with methylprednisolone (MP) on lipid peroxidation and antioxidants after spinal cord injury (SCI) in rats.
DFO is used for treating an iron-chelating agent, which is also used in the treatment of iron poisoning and thalassaemia. The neuroprotective effect of DFO was evaulated as a therapeutic agent for SCI.
Forty Wistar rats were randomly divided into 5 groups as sham laminectomy (n = 8), laminectomy with SCI (n = 8), laminectomy with SCI and 0.9% saline intraperitoneal (i.p.) (n = 8), laminectomy with SCI and 30 mg/kg MP i.p. (n = 8), and laminectomy with SCI and 30 mg/kg DFO i.p. (n = 8). Neurological deficits were examined 24 hours after trauma, and all rats were killed. Spinal cord segments were harvested for both biochemical and histopathological evaluation.
At 24 hours post-SCI, whereas malondialdehyde levels were increased, superoxide dismutase, catalase, and glutathione peroxidase levels were decreased in groups I, II, and III. MP and DFO treatment decreased MDA levels and increased superoxide dismutase CAT, and glutathione peroxidase levels in control and study groups. There was no statistically significant difference between treatment with MP and DFO (P> 0.05). All rats were paraplegic after SCI, except in the sham group. Histopathological improvement was observed in control and study groups.
This study indicates that beneficial effects may be provided and further studies need to investigate the dose-dependent beneficial and side effects of DFO in SCI.
Level of Evidence: N/A
We investigate the protective effect of deferoxamine (DFO) administration in comparison with methylprednisolone (MP) on lipid peroxidation and antioxidants after spinal cord injury (SCI) in rats.
*Department of Neurosurgery, Eyup Government Hospital, Istanbul, Turkey
†Department of Neurosurgery, Bayindir Icerenkoy Hospital, Istanbul, Turkey; and Departments of
¶Pathology, Haydarpasa Training Hospital, Gulhane Military Medical Academy, Istanbul, Turkey.
Address correspondence and reprint requests to Cem Dinc, MD, Icerenkoy Emniyet Cik. Sk. Aydin Kardesler Apt, 4/16 34752 Kadikoy, Istanbul, Turkey; E-mail: email@example.com
Acknowledgment date: June 11, 2013. First revision date: August 5, 2013. Second revision date: September 10, 2013. Acceptance date: September 16, 2013.
The device(s)/drug(s) that is/are the subject of the manuscript is/are not intended for human use.
No funds were received in support of this work.
No relevant financial activities outside the submitted work.